 AnaptysBio Incs NASDAQ: ANAB stock seems attractive after the POPLAR data and the 30 selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients, according to its website. 